Tuesday, September 07, 2010 8:35:37 AM
New Patents Expand Coverage for Imaging and Therapeutic Applications of Peregrine's Phospholipid-Targeting Technologies
• Claims Cover Additional Phospholipid Targets and Antibodies to Image Tumor Vasculature and Treat Viral Infections
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=505041
TUSTIN, Sept 7, 2010: Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the issuance of two U.S. patents providing protection for tumor vasculature imaging and antiviral applications of a broad range of phospholipid-targeting antibodies. Expanding upon Peregrine's previously established claims covering tumor imaging and antiviral applications of certain phosphatidylserine (PS)-targeting antibodies, these two new patents cover:
-- Methods of imaging tumor vasculature using phosphatidylserine (PS) and
phosphatidylethanolamine (PE)-targeting antibodies and certain other
proteins. This patent, which does not expire until 2019, includes
methods for imaging vascularized tumors using any antibody that binds
to PS or PE, either directly or indirectly, as well as combined
imaging and therapeutic methods.
-- Combined antiviral compositions and viral treatment methods using a
broad range of antibodies and immunoconjugates, including any antibody
that binds to PS, either directly or indirectly. This patent, which
could extend until 2027, therefore covers antiviral compositions and
viral treatment methods using bavituximab and fully human counterparts
to bavituximab.
"Issuance of these patents increases the scope of our intellectual property and increases the value of our proprietary PS-targeting platform," said Steven W. King, president and CEO of Peregrine. "As the leader in PS-targeting antibodies with demonstrated broad therapeutic potential against multiple cancers and viral infections, we have been strategic in building a strong patent portfolio protecting the composition, treatment methods, and imaging applications of this first-in-class technology. We plan to continue to strengthen our patent estate, increasing the potential value of our overall phospholipid-targeting platform."
Peregrine's lead PS-targeting antibody bavituximab is being evaluated in combination with standard chemotherapy in two Phase IIb trials in refractory and front-line non-small cell lung cancer (NSCLC) patients and a Phase Ib trial in patients coinfected with Hepatitis C virus (HCV) and HIV.
U.S. Patent Nos. 7,790,860 and 7,790,159, which were issued today, were granted to the University of Texas System and are exclusively licensed to Peregrine Pharmaceuticals.
[ USPO Links:
• 7,790,860: Targeting and imaging tumor vasculature using conjugates that bind to aminophospholipids
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7,790,860.PN.&OS=PN/7,790,860
• 7,790,159: Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7,790,159.PN.&OS=PN/7,790,159 ]
ABOUT PEREGRINE PHARMACEUTICALS
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara(R). Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( http://www.avidbio.com ), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com .
Safe Harbor *snip*
Contact:
Amy Figueroa, Peregrine Pharmaceuticals, (800) 987-8256, info@peregrineinc.com
= = = = = = = = = = =
The Inventor of the Anti-PS mab ‘3G4/bavituximab’ is Dr. Philip E. Thorpe of UTSW-MC/Dallas.
BIO: http://www.utsouthwestern.edu/findfac/research/0,2357,17308,00.html
...Thorpe's LAB TEAM: http://tinyurl.com/yuxemu
DR. THORPE'S PATENTS:
. . .GRANTED: http://tinyurl.com/m232k
. . .PENDING: http://tinyurl.com/845p2
DR. THORPE'S ARTICLES: http://tinyurl.com/csjsl
Recent CDMO News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:32:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:31:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:30:26 AM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM